Valtoco Generic: When Will Generic Diazepam Be Available?
This page is aggregated from FDA records, court filings and company announcements. Coded and designed by Dr. Brian Staiger, PharmD, BCPS
Updated October 9, 2026 How we build our data
Valtoco Generic at a Glance
Four quick answers from FDA records and our estimate.
- When is the first generic expected? 2030 to 2031 A wide window Why then?
- Has the FDA approved a generic? Not yet None in the FDA’s records yet Why not yet?
- When does the last patent end? June 2042 8 patents listed with the FDA Why is a generic expected sooner?
- Can you buy a generic today? Not yet No company lists one for sale
Generic diazepam is expected to be available between 2030 and 2031. None is for sale yet.
Why 2030 to 2031?
The patent fight is likely to end in an agreement that sets the launch. The terms are not public yet. We rate it probable: more likely than not, but it can still move.
If Valtoco’s last patent runs to June 2042, how can a generic come sooner?
The 3 patents that run past the expected month, to June 2042 (12,337,061, 12,324,852 and 12,599,611), cover a way of using it. A patent like that protects one way of making or using the medicine, not the medicine itself. A generic company can often make its version a different way or leave that use off its label, or a court can rule the patent invalid or not infringed. Here, the companies are expected to settle on a date. Generic companies have been challenging Valtoco’s patents with the FDA since February 2024. That is why the expected month comes before the last protection ends. See the road to a generic
Why hasn’t the FDA approved a generic yet?
That is normal before a launch. The FDA usually can’t give a generic its final approval while a patent or exclusivity still blocks it, so final approval often comes close to the day the generic can be sold. No company holds a “tentative” approval yet either (the FDA’s word for a generic that is ready but still blocked).
Will the generic cost less?
Usually, and more so as more companies sell one. 4 companies have applied to the FDA to make it. In the FDA’s study of past launches, pharmacies paid about 73% less once four companies sold a generic, which would take the $366.14 pharmacies pay each for Valtoco today to about $98.86. See the price estimate
What should I do now?
Keep taking Valtoco as prescribed. When a generic arrives, your pharmacy may switch you to it automatically, and it may look different. What a generic means for you
Our month is only an estimate based on available information, so we never name a day.
Valtoco by the Numbers
- Reason
- Settlement expectedThe patent fight is likely to end in an agreement that sets the launch. The terms are not public yet.
- How sure
- Probable More likely than not, but it can still move.
- Price competition
- Strong 4 companies have filed, 2 first in line
- Brand sales
- Sales not reported
- FDA approved 2020 January 2020 FDA Orange Book
- Patents listed 8 last runs to June 2042 A generic is expected sooner, between 2030 and 2031. See why FDA Orange Book
- Pharmacies pay $366.14 each NADAC, October 2026
- Medicare Part D spent $37.8M in 2025, for 10.7K people CMS Part D Spending by Drug
- Medicaid prescriptions 167.8K in the last four reported quarters, $295.6M CMS Medicaid drug utilization, to Q1 2026
Valtoco’s Road to a Generic
Valtoco has had the market to itself since the FDA approved it in January 2020 (Neurelis Inc). Its FDA protection (new patient population) runs to April 2028. Its 8 listed patents run to June 2042. Generic companies have challenged its patents with the FDA since February 2024.
The first generic of Valtoco is expected between 2030 and 2031.
Why that month: the patent fight is likely to end in an agreement that sets the launch. The terms are not public yet.
Why a Generic Can Come Before June 2042
The last listed patent runs to June 2042, but it covers a way of using it, not the medicine itself, which a generic can often work around or challenge. Dr. Brian explains
Each bar runs from the brand’s approval to the day that protection ends. The green band is our projection for the first generic: a month, never a day, because legal dates move and a generic reaches shelves days to weeks after it is allowed. Sources: FDA Orange Book; the expected month from court records and company announcements.
Valtoco Patents and FDA Protections
Every patent and exclusivity the FDA Orange Book lists for Valtoco’s own applications. A protection running past the expected month does not mean the date is wrong: a settlement or a court ruling can let a generic in before a patent ends, and a patent on one formulation or use does not block every generic.
| Patent | What it covers | Protects until | Status |
|---|---|---|---|
| 8,895,546 | The product’s formulation | March 2029 | Active |
| 11,241,414 | The product’s formulation | March 2029 | Active |
| 11,793,786 | The product’s formulation | March 2029 | Active |
| 12,268,664 | The product’s formulation | March 2029 | Active |
| 12,521,400 | The product’s formulation | March 2029 | Active |
| 12,337,061 | A way of using it (U-4173) | June 2032 | Active |
| 12,324,852 | A way of using it (U-4173) | October 2032 | Active |
| 12,599,611 | A way of using it (U-4455) | June 2042 | Active |
| Exclusivity | What it means | Ends | Status |
|---|---|---|---|
| Orphan drug ODE-279 | Seven years of protection for a use in a rare disease. | January 2027 | Active |
| New patient population NPP | Three years of protection for a newly approved group of patients. | April 2028 | Active |
Source: FDA Orange Book, application 211635. Patent numbers open the patent on Google Patents.
Patent Challenges to Valtoco
The first patent challenge to Valtoco reached the FDA in February 2024, from one company on that first day. The FDA’s list has 2 entries for Valtoco, by form and strength. The FDA has not approved a first challenger’s generic yet.
What Is a Patent Challenge?
A generic company that wants to sell its version before Valtoco’s patents run out can tell the FDA that a patent is invalid, or that its version does not infringe it. The FDA calls this a “Paragraph IV certification.” The brand company usually sues, and the FDA then generally cannot approve that generic for up to 30 months while the case runs. To reward going first, the companies that challenge first can get a 180-day head start: the FDA cannot approve the generics that came after them until it ends.
| Product | First challenged | Companies that day | 180-day head start | First challenger’s generic | Challenged patents run to | |
|---|---|---|---|---|---|---|
| Approved | On sale | |||||
| Nasal spray, 10 mg/spray | February 2024 | 1 company | No decision yet | Not yet | Not yet | March 2029 |
| Nasal spray, 5 mg/spray and 7.5 mg/spray | April 2025 | 1 company | No decision yet | Not yet | Not yet | March 2029 |
Source: the FDA’s Paragraph IV Patent Certifications list, as of September 2026. The FDA began posting the 180-day decisions and the first challenger’s approval and first sale in June 2019: an older entry it has not updated since reads “Not posted”, and “Not yet” means the list records no such event. “Companies that day” is the FDA’s count of challenges that arrived on the first day.
Who Is Lined Up to Make Generic Diazepam
Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.
Applied to the FDA
4 companies have applied to the FDA to make generic diazepam.
The FDA names a company only once it approves its application, even tentatively, and it has not done that for these yet, so the companies are not named here. Names often come out in the brand company’s patent lawsuits or in the companies’ own announcements.
First in line. 2 of them were first in line, both filing on the first day any company did: they can share 180 days on the market before the other generics, which is why being first matters.
Generic companies have challenged Valtoco’s patents with the FDA since February 2024: see the patent challenges.
Approved by the FDA
Not yet. The FDA has not approved a generic diazepam. Final approval often comes close to the day a generic can be sold.
For Sale in Pharmacies
Not yet. No company lists a generic diazepam for sale with the FDA.
Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; tentative approvals from Drugs@FDA; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).
Valtoco Price: What Pharmacies Pay and What Generics Usually Do
What Pharmacies Pay for Valtoco 5 mg nasal spray
$366.14 each in October 2026.
Hover over or tap anywhere on the chart to see that month’s price.
- Valtoco 5 mg nasal spray $366.14 each
- Valtoco 10 mg nasal spray $365.47 each
- Valtoco 15 mg nasal spray $365.51 each
- Valtoco 20 mg nasal spray $365.64 each
See the numbers
| Month | Pharmacies paid each |
|---|---|
| October 2026 | $366.14 |
| September 2026 | $366.14 |
| August 2026 | $366.23 |
| July 2026 | $366.16 |
| June 2026 | $365.78 |
| May 2026 | $365.32 |
| April 2026 | $366.43 |
| March 2026 | $366.43 |
| February 2026 | $366.43 |
| January 2026 | $366.43 |
NADAC: the national average price retail pharmacies pay to buy the medicine (CMS survey, updated weekly), the last price of each month for one package. It is not what you pay: that depends on your insurance or discount card.
What a Generic Could Cost
How we estimate it. We start from what pharmacies pay for Valtoco today: $366.14 each for Valtoco 5 mg nasal spray in October 2026, from the national NADAC survey. Then we apply the FDA’s finding of how far that price usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017). Valtoco has 4 companies lined up, so our estimate uses the figure for four companies. More companies would bring the price lower; fewer, less of a drop.
Dollar figures apply FDA’s median drops to the $366.14 pharmacies pay each today. An estimate from the pattern, not a price quote: what you pay depends on your insurance or discount card.
Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.
What Medicare and Medicaid Spend on Valtoco
Big public spending is part of why generic makers line up for a medicine, and why its first generic matters beyond the pharmacy counter. Figures are before manufacturer rebates, which are confidential.
Medicare Part D Spending
What Medicare drug plans spent on Valtoco, before manufacturer rebates.
- $11.9M
- January to March 2026, the latest CMS has posted
For 4,398 people, about $2,048 per prescription fill - $37.8M
- 2025, the whole year
For 10,724 people, about $1,683 per prescription fill
See the numbers
| Period | Spending | People | Per fill |
|---|---|---|---|
| January to March 2026 | $11,913,093 | 4,398 | $2,047.63 |
| 2025 | $37,776,682 | 10,724 | $1,683.30 |
Source: CMS Medicare Part D Spending by Drug, matched by the brand name Valtoco only, so no generic is counted in it. What CMS says it is used for: This medication is used by people with epilepsy to treat a certain type of serious seizure that doesn't stop (seizure clusters). Diazepam belongs to a class of drugs known as benzodiazepines.
Medicaid Prescriptions by Quarter
167,793 prescriptions in the four quarters to Q1 2026, $295.6M paid.
See the numbers
| Quarter | Prescriptions | Medicaid paid |
|---|---|---|
| Q1 2026 | 39,000 | $73,608,003 |
| Q4 2025 | 41,686 | $75,815,177 |
| Q3 2025 | 53,044 | $94,896,342 |
| Q2 2025 | 34,063 | $51,301,028 |
| Q1 2025 | 40,440 | $38,543,821 |
Source: CMS Medicaid State Drug Utilization Data, over Valtoco’s own package codes.
Valtoco Strengths and Forms
| Strength | Form | How it is taken | Approved | Status |
|---|---|---|---|---|
| 10MG/SPRAY | Spray | Nasal | January 2020 | Prescription reference product |
| 5MG/SPRAY | Spray | Nasal | January 2020 | Prescription reference product |
| 7.5MG/SPRAY | Spray | Nasal | January 2020 | Prescription reference product |
Source: FDA Orange Book, Neurelis Inc. Listed for sale today by Neurelis, Inc (FDA NDC Directory).
Valtoco NDC Codes and Packages
Each Valtoco package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.
| NDC | Product | Package | Company |
|---|---|---|---|
| 72252-0510-02 | DIAZEPAM 10 mg/.1mL spray | carton of 2 blister packs of 1 vial of .1 mL | Neurelis, Inc |
| 72252-0510-02 | DIAZEPAM 10 mg/.1mL spray | carton of 2 blister packs of 1 vial of .1 mL | Neurelis, Inc |
| 72252-0510-05 | DIAZEPAM 10 mg/.1mL spray | carton of 5 blister packs of 1 vial of .1 mL | Neurelis, Inc |
| 72252-0520-04 | DIAZEPAM 10 mg/.1mL spray | carton of 2 blister packs of 2 vials of .1 mL | Neurelis, Inc |
| 72252-0520-04 | DIAZEPAM 10 mg/.1mL spray | carton of 2 blister packs of 2 vials of .1 mL | Neurelis, Inc |
| 72252-0520-10 | DIAZEPAM 10 mg/.1mL spray | carton of 2 blister packs of 2 vials of .1 mL | Neurelis, Inc |
| 72252-0505-02 | DIAZEPAM 5 mg/.1mL spray | carton of 2 blister packs of 1 vial of .1 mL | Neurelis, Inc |
| 72252-0505-02 | DIAZEPAM 5 mg/.1mL spray | carton of 2 blister packs of 1 vial of .1 mL | Neurelis, Inc |
Show the other 4 Valtoco packages
| NDC | Product | Package | Company |
|---|---|---|---|
| 72252-0505-05 | DIAZEPAM 5 mg/.1mL spray | carton of 5 blister packs of 1 vial of .1 mL | Neurelis, Inc |
| 72252-0515-04 | DIAZEPAM 7.5 mg/.1mL spray | carton of 2 blister packs of 2 vials of .1 mL | Neurelis, Inc |
| 72252-0515-04 | DIAZEPAM 7.5 mg/.1mL spray | carton of 2 blister packs of 2 vials of .1 mL | Neurelis, Inc |
| 72252-0515-10 | DIAZEPAM 7.5 mg/.1mL spray | carton of 5 blister packs of 2 vials of .1 mL | Neurelis, Inc |
Source: the FDA NDC Directory, current listings only. Only packages sold under Valtoco’s own FDA approval (NDA 211635) are listed, never a generic. Some codes belong to companies that repackage Valtoco: it is the same medicine in a different package.
What a Generic Valtoco Means for You
Nothing Changes Until It Is in Pharmacies
Until a generic is actually for sale, keep filling Valtoco as usual. When one arrives, there is nothing you need to sign up for.
Your Pharmacy May Switch You Automatically
Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.
It Will Probably Look Different
US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.
Your Insurance May Change Too
Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.
Until a generic is on US pharmacy shelves, be careful with websites that offer “generic Valtoco”. The FDA warns that unlicensed online pharmacies sell counterfeit and unapproved medicines; its BeSafeRx page shows how to check a pharmacy.
Questions people ask about Valtoco
Is there a generic for Valtoco right now?
No. As of October 9, 2026 no generic diazepam is listed for sale in the FDA NDC Directory.
When will Valtoco go generic?
2030 to 2031 is the expected window, and that is probable but not certain. The patent fight is likely to end in an agreement that sets the launch. The terms are not public yet. The last listed patent runs to June 2042, but it covers a way of using it, not the medicine itself, which a generic can often work around or challenge.
Will generic diazepam be the same as Valtoco?
Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.
How much will the generic cost?
Nobody can say for sure before launch. 4 companies have applied to the FDA to make it. In the FDA’s study of past launches, pharmacies paid about 73% less once four companies sold a generic, which would take the $366.14 pharmacies pay each for Valtoco today to about $98.86. That is a pattern from past launches, not a prediction for this one.
Has the FDA approved a generic Valtoco?
Not yet. The FDA Orange Book lists no approved generic version of Valtoco.
When does the Valtoco patent expire?
The FDA Orange Book lists 8 patents for Valtoco; the last runs to June 2042. A patent date is not the launch date: settlements and court rulings often bring a generic earlier, and FDA approval or a company’s own plans can make it later. The expected window on this page (2030 to 2031) weighs all of that.
Has anyone challenged the Valtoco patents?
Yes. The first patent challenge to Valtoco reached the FDA in February 2024, from one company on that first day. The FDA has not approved a first challenger’s generic yet. A patent challenge (a “Paragraph IV certification”) is a generic company telling the FDA that a patent listed for the brand is invalid or will not be infringed by its version. The first companies to file one can earn a 180-day head start, during which the FDA cannot approve the generics that filed after them.
How much does Valtoco cost now?
Pharmacies paid about $366.14 each for Valtoco 5 mg nasal spray in October 2026, by the national survey of what pharmacies pay (NADAC). That is the pharmacy’s cost, not your price: what you pay depends on your insurance or discount card.
Changes to This Projection
- First generic expected 2030 to 2031 on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.
Every change to the expected month is logged here with the month we saw it.
Also Going Generic
- BelrapzoBendamustine HydrochlorideJanuary 2031
- SynjardyEmpagliflozin and Metformin2032 to 2033
- XenletaLefamulinMarch 2033
- EvrysdiRisdiplam2036 to 2037
- KygevviDoxecitine and DoxribtimineJuly 2043
- OxaydoOxycodone HydrochlorideTBD no date yet
About Valtoco
- Generic name diazepam
- How it is taken In the nose
- Company Neurelis Inc
- Hard to copy Inhalers, injectables, patches and other hard-to-copy products. Fewer companies attempt them and dates slip more often.
- Patent challenges Since February 2024 (FDA)
- More drugs Brand-name drugs starting with V
- Have a question? A pharmacist answers, free. Ask about Valtoco
Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, Drugs@FDA (tentative approvals), FDA NDC Directory, FDA Paragraph IV Patent Certifications list, NADAC (CMS), CMS Medicare Part D Spending by Drug, Medicaid State Drug Utilization Data, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.